Logo

Steven Verdooner, Richard Lai Fatt

Jun 07, 2007
Premium
eXegenics said this week that it has named Steven Verdooner as its executive vice president of instrumentation.
 
Verdooner previously held various managerial positions at Ophthalmic Imaging Systems, an ophthalmic digital imaging and informatics firm he co-founded.
 
eXegenics announced the hiring of Verdooner when it reported an agreement to buy ophthalmic imaging and diagnostics company Ophthalmic Technologies.
 
 
Nventa Biopharmaceuticals said this week that it has appointed Richard Lai Fatt as its vice president of corporate development.
 
Lai Fatt previously was vice president of business development and strategic marketing at antisense firm Isis Pharmaceuticals.
 
 
Biogen Idec said this week that it has appointed Marijn Dekkers to its board of directors.
 
Dekkers is president and CEO of Thermo Fisher Scientific.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.